4D Molecular Therapeutics, Inc.
FDMT
$3.11
-$0.02-0.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.00K | 37.00K | 17.00K | 20.22M | 20.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.00K | 37.00K | 17.00K | 20.22M | 20.45M |
| Cost of Revenue | 154.13M | 141.30M | 124.24M | 110.82M | 102.55M |
| Gross Profit | -154.11M | -141.26M | -124.23M | -90.61M | -82.10M |
| SG&A Expenses | 49.22M | 46.58M | 44.15M | 40.61M | 38.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 203.35M | 187.88M | 168.39M | 151.44M | 141.35M |
| Operating Income | -203.33M | -187.84M | -168.38M | -131.22M | -120.90M |
| Income Before Tax | -176.44M | -160.87M | -143.48M | -109.89M | -104.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -176.44 | -160.87 | -143.48 | -109.89 | -104.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -176.44M | -160.87M | -143.48M | -109.89M | -104.56M |
| EBIT | -203.33M | -187.84M | -168.38M | -131.22M | -120.90M |
| EBITDA | -198.80M | -183.19M | -163.72M | -126.76M | -116.55M |
| EPS Basic | -3.17 | -2.97 | -2.83 | -2.29 | -2.43 |
| Normalized Basic EPS | -1.98 | -1.86 | -1.77 | -1.43 | -1.52 |
| EPS Diluted | -3.17 | -2.97 | -2.83 | -2.29 | -2.43 |
| Normalized Diluted EPS | -1.98 | -1.86 | -1.77 | -1.43 | -1.52 |
| Average Basic Shares Outstanding | 222.22M | 215.75M | 202.98M | 189.68M | 172.73M |
| Average Diluted Shares Outstanding | 222.22M | 215.75M | 202.98M | 189.68M | 172.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |